Home Newsfeeds Donald Trump Posts On Facebook Announcing He Has Returned To Platform

Donald Trump Posts On Facebook Announcing He Has Returned To Platform

https://www.facebook.com/DonaldTrump/

byMichael Horton

March 17, 2023

1 minute read

https://www.facebook.com/DonaldTrump/

Maxine Waters Says Lawmakers Are ‘Very, Very Close’ To Finalizing Stablecoin Regulation Bill

By Mehab Qureshi

February 8, 1:25 AM

Rep. Maxine Waters (D-Calif.) said in an interview on Wednesday that a deal on the stablecoin bill is nearly complete.

BTC

ZimVie Announces Anthem Blue Cross Blue Shield Issued Positive Policy Decision Applicable To Anterior Vertebral Body Tethering

By Bill Haddad

July 12, 8:06 AM

ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental and spine markets, today announced that Anthem Blue Cross Blue Shield (BCBS), a subsidiary/operating company of Elevance Health, has issued a

ZIMV

Benchmark Initiates Coverage On LiveRamp Holdings with Hold Rating

By Benzinga Newsdesk

September 20, 5:14 AM

Benchmark analyst Mark Zgutowicz initiates coverage on LiveRamp Holdings (NYSE:RAMP) with a Hold rating.

RAMP

Allogene Therapeutics Announces Encore Presentation Of Phase 1 Data From The ALLO-501/501A Trials In Large B Cell Lymphoma At The European Hematology Association Hybrid Congress

By Happy Mohamed

May 11, 11:51 AM

Data Will Also Be Presented in a Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2023 SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics,

ALLO

Donald Trump Posts On Facebook Announcing He Has Returned To Platform

Related Posts

Maxine Waters Says Lawmakers Are ‘Very, Very Close’ To Finalizing Stablecoin Regulation Bill

ZimVie Announces Anthem Blue Cross Blue Shield Issued Positive Policy Decision Applicable To Anterior Vertebral Body Tethering

Benchmark Initiates Coverage On LiveRamp Holdings with Hold Rating

Allogene Therapeutics Announces Encore Presentation Of Phase 1 Data From The ALLO-501/501A Trials In Large B Cell Lymphoma At The European Hematology Association Hybrid Congress